PCRX Pacira BioSciences, Inc.
$36.40▲ +0.06%
Healthcare
Other
After hours
$36.40▲ +0.00%
Oct 27, 4:01 PM ET
Volume 471.8K
Avg Volume (10D) 1.34M
Key Metrics & Fundamentals
Market Cap
$1.45B
P/E Ratio
104.0
Div Yield
0.00%
52W Range
18.80 - 36.67
% vs 50 MA
28.51%
% vs 200 MA
47.79%
RSI-14
83.4
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.10
Free Cash Flow
$56.12M
Gross Rev
$192.40M
Gross Profit
$148.24M
EBITDA
$34.55M
COGS
$44.16M
Operating Exp
$136.37M
Operating Income
$11.86M
EBIT
$11.86M
Pretax Income
$2.56M
Net Income
$4.65M
EPS (Diluted)
0.12
Price & Volume History
Loading chart…
Recent News
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
Stocktwits · Oct 27, 2026 3:14 AM ET
ETFs Are Net Sellers of Pacira BioSciences (PCRX) on Oct. 22
GuruFocus.com · Oct 26, 2026 7:03 AM ET
Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing
Simply Wall St. · Oct 23, 2026 12:13 PM ET
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits · Oct 12, 2026 2:32 AM ET
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits · Oct 9, 2026 9:12 PM ET
Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says
MT Newswires · Oct 9, 2026 11:23 AM ET
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Zacks · Oct 9, 2026 9:37 AM ET
HC Wainwright Downgrades Pacira Biosciences to Neutral, Price Target is $36.50
MT Newswires · Oct 9, 2026 7:24 AM ET
Oppenheimer Downgrades Pacira Biosciences to Perform From Outperform on Heels of Announced Sale to Viatris
MT Newswires · Oct 9, 2026 4:53 AM ET
Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus
Simply Wall St. · Oct 9, 2026 2:09 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PCRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.